Registered title, quoted from ClinicalTrials.gov
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07638787, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Patients with newly diagnosed large B-cell lymphoma confirmed by histopathology, CD20-positive, excluding central nervous system lymphoma;
Inclusion criterion 1
Measurable lesions confirmed by radiological examination, defined as: at least one lymph node lesion with the longest diameter > 1.5 cm, or at least one extranodal lesion with the longest diameter > 1.0 cm, and at least two accurately measurable perpendicular diameters;
Inclusion criterion 8
Participants with a history of untreated low-grade early-stage prostate cancer (Gleason score ≤ 6, Stage 1 or 2) at any time before the study are eligible to participate;
Exclusion criterion 19
Participants who received adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer for ≥ 2 years before enrollment are eligible to participate;
Exclusion criterion 20
History of immune-related adverse events following prior immunotherapy drug-related treatment, as follows: known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (excluding onychomycosis) at study enrollment, or major infections within 4 weeks before the start of Cycle 1;
Exclusion criterion 22
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
Inclusion criterion 7
Neutrophils < 1.0×10⁹/L;
Exclusion criterion 5
Platelets < 75×10⁹/L;
Exclusion criterion 6
Serum AST and ALT ≥ 2.5× upper limit of normal (ULN);
Exclusion criterion 7
Total bilirubin ≥ 1.5×ULN;
Exclusion criterion 8
Serum creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault formula);
Exclusion criterion 9
Patients infected with human immunodeficiency virus (HIV);
Exclusion criterion 16
Active hepatitis B virus (HBV) infection (positive result by PCR). For patients with positive HBsAg test results, HBV DNA test is required; if HBV DNA < 10³ IU/ml, they can be enrolled. If HBsAg test result is negative but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required; if HBV DNA < 10³ IU/ml, they can be enrolled;
Exclusion criterion 23
Positive hepatitis C test result (serological test for hepatitis C virus [HCV] antibody):
Exclusion criterion 24
Eligibility to participate is only allowed if the PCR test result for HCV RNA is negative in patients with positive HCV antibody;
Exclusion criterion 25
Currently pregnant or breastfeeding, or planning to become pregnant during the study or within 12 months after the last dose;
Exclusion criterion 27
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07638787, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients with newly diagnosed large B-cell lymphoma confirmed by histopathology, CD20-positive, excluding central nervous system lymphoma;
- Patients aged 18 to 75 years;
- International Prognostic Index score of 2 to 5;
- Patients with high BCL-2 expression or double-hit lymphoma characteristics;
- No prior anti-tumor treatment of any type;
- Estimated survival time ≥ 6 months;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
- Measurable lesions confirmed by radiological examination, defined as: at least one lymph node lesion with the longest diameter > 1.5 cm, or at least one extranodal lesion with the longest diameter > 1.0 cm, and at least two accurately measurable perpendicular diameters;
- Patients or their legal representatives must provide written informed consent before conducting any study-specific examinations or procedures;
- No prior treatment for lymphoma (except glucocorticoids).
Exclusion Criteria:
- Prior solid organ transplantation or stem cell transplantation;
- Complicated with uncontrolled coagulation disorders, connective tissue diseases, severe infectious diseases, etc.;
- Suspected active or latent tuberculosis (confirmed by a positive interferon-gamma release assay);
- Any of the following abnormal laboratory test values (unless these abnormalities are all caused by the underlying lymphoma):
- Neutrophils < 1.0×10⁹/L;
- Platelets < 75×10⁹/L;
- Serum AST and ALT ≥ 2.5× upper limit of normal (ULN);
- Total bilirubin ≥ 1.5×ULN;
- Serum creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault formula);
- Uncontrolled or significant cardiovascular diseases, including but not limited to:
- Left ventricular ejection fraction (LVEF) < 50%;
- Primary cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.;
- Clinically significant QTc prolongation, with QTc interval > 470 ms (females) or 480 ms (males), second-degree type II atrioventricular block, or third-degree atrioventricular block;
- Current or past history of central nervous system (CNS) diseases, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative diseases. However, participants with a history of stroke who have not had a stroke or transient ischemic attack in the past 2 years and have no residual neurological deficits as judged by the investigator are allowed to participate in the study;
- Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
- Patients infected with human immunodeficiency virus (HIV);
- History of other malignant tumors that may affect protocol compliance or interpretation of results:
- Participants with a history of cured basal or squamous cell carcinoma of the skin, melanoma, or carcinoma in situ of the cervix at any time before the study are eligible to participate;
- Participants with a history of untreated low-grade early-stage prostate cancer (Gleason score ≤ 6, Stage 1 or 2) at any time before the study are eligible to participate;
- Participants who received adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer for ≥ 2 years before enrollment are eligible to participate;
- Participants with any other malignant tumor cured by appropriate radical treatment and in remission without treatment for ≥ 2 years before enrollment are eligible to participate;
- History of immune-related adverse events following prior immunotherapy drug-related treatment, as follows: known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (excluding onychomycosis) at study enrollment, or major infections within 4 weeks before the start of Cycle 1;
- Active hepatitis B virus (HBV) infection (positive result by PCR). For patients with positive HBsAg test results, HBV DNA test is required; if HBV DNA < 10³ IU/ml, they can be enrolled. If HBsAg test result is negative but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required; if HBV DNA < 10³ IU/ml, they can be enrolled;
- Positive hepatitis C test result (serological test for hepatitis C virus [HCV] antibody):
- Eligibility to participate is only allowed if the PCR test result for HCV RNA is negative in patients with positive HCV antibody;
- Participants with a history of progressive multifocal leukoencephalopathy (PML);
- Currently pregnant or breastfeeding, or planning to become pregnant during the study or within 12 months after the last dose;
- Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study.
Quoted from ClinicalTrials.gov, NCT07638787, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07638787, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.